div class=ts-pagebutton class=gotoPage data-page=1Page 1button div class=ts-imageimg data-url=-segunda-enfermedad-linfoproliferativa-post-trans-plante-2qelpt-en-dos-pacienteshtmlpage=1 data-page=1 class=ts-thumb lazyload alt=Page 1: · SEGUNDA ENFERMEDAD LINFOPROLIFERATIVA POST TRANS- PLANTE 2QELPT EN DOS PACIENTES PEDIÁTRICOS TRANSPLAN- TADOS HEPÁTICOS LGL representa del 2-5% de las neoplasias TNK loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsmxreader031viewer20220217005c65d4fa09d3f2ad6e8d3be9html5thumbnails1jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=2Page 2button div class=ts-imageimg data-url=-segunda-enfermedad-linfoproliferativa-post-trans-plante-2qelpt-en-dos-pacienteshtmlpage=2 data-page=2 class=ts-thumb lazyload alt=Page 2: · SEGUNDA ENFERMEDAD LINFOPROLIFERATIVA POST TRANS- PLANTE 2QELPT EN DOS PACIENTES PEDIÁTRICOS TRANSPLAN- TADOS HEPÁTICOS LGL representa del 2-5% de las neoplasias TNK loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsmxreader031viewer20220217005c65d4fa09d3f2ad6e8d3be9html5thumbnails2jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=3Page 3button div class=ts-imageimg data-url=-segunda-enfermedad-linfoproliferativa-post-trans-plante-2qelpt-en-dos-pacienteshtmlpage=3 data-page=3 class=ts-thumb lazyload alt=Page 3: · SEGUNDA ENFERMEDAD LINFOPROLIFERATIVA POST TRANS- PLANTE 2QELPT EN DOS PACIENTES PEDIÁTRICOS TRANSPLAN- TADOS HEPÁTICOS LGL representa del 2-5% de las neoplasias TNK loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsmxreader031viewer20220217005c65d4fa09d3f2ad6e8d3be9html5thumbnails3jpg width=140 height=200 divdiv
